CLOs on the Move

ZyStor Therapeutics

www.zystor.com

 
ZyStor Therapeutics is a Milwaukee, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.zystor.com
  • 10437 W Innovation Dr Ste 100
    Milwaukee, WI USA 53226
  • Phone: 414.727.9777

Executives

Name Title Contact Details

Similar Companies

Airway Therapeutics

Airway Therapeutics has extensive expertise in protein development for applications in the lungs and pediatrics.

Hamilton

The leader in liquid handling equipment and laboratory automation technology, Hamilton Robotics is recognized for advancing life science and biotechnology industries with products that offer reliability, performance and flexibility. Hamilton is the ind...

Synsorb Biotech

Synsorb Biotech Inc. is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Aruvant

Aruvant`s mission is to bring hope to patients living with rare diseases by developing life changing and potentially curative gene therapies, with a near-term focus on sickle cell disease. Aruvant is a part of the Roivant family of companies. We have a talented team with extensive experience in the development, manufacturing and commercialization of gene therapy products. We have an active research program with a lead product candidate in development for individuals suffering from sickle cell disease (SCD). Our lead product candidate, ARU-1801, an investigational lentiviral gene therapy, is currently in a clinical trial as a potential one-time curative treatment for SCD. Preliminary clinical data from the ongoing Phase 1/2 study demonstrated durable efficacy in reducing the negative impacts of SCD. We are preparing for the launch of our pivotal clinical trial in SCD. We continue to look for new people to add to our talented team.

Thrive Bioscience

Thrive Bioscience`s unique solutions increase the speed, quality, and cost-effectiveness of drug discovery and basic research while enabling the delivery of new therapies through improving the cell culture and stem cell culture processes.